HomeBUSINESS
BUSINESS

Hep C Market Shrinking towards Disease Elimination in 2030
(Oct.12.2018)

AbbVie Japan President James Feliciano
By Reiji Anasako

AbbVie’s hepatitis C drug Maviret (glecaprevir + pibrentasvir) was by far the best-selling medicine in Japan in April-September, but its sales appear to have already peaked out thanks to its own success. The shrinking market signals that the industry is on track to the elimination of the disease by 2030, as advocated by the WHO ...
(LOG IN FOR FULL STORY)